Navigation Links
SuperGen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference on November 10, 2008
Date:11/3/2008

DUBLIN, Calif., Nov 3 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that James S. Manuso, Ph.D., President and Chief Executive Officer, is scheduled to present at the Rodman & Renshaw 10th Annual Healthcare Conference on Monday, November 10, 2008, at the New York Palace Hotel.

SuperGen's presentation at the Rodman & Renshaw 10th Annual Healthcare Conference is scheduled to begin at 11:35 a.m. EDT (8:35 a.m. PDT). A live webcast of the presentation will be available on the investor relations section of the Company's Web site at http://www.supergen.com. The webcast will be archived for 90 days.

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Contacts:

SuperGen, Inc.

Timothy L. Enns

SVP, Corporate Communications

& Business Development

Tel: (925) 560-0100

Email: tenns@supergen.com

Mary M. Vegh

Manager, Investor Relations

Tel: (925) 560-2845

E-mail: mary.vegh@supergen.com

Dorland Global Public Relations

Michael Beckerich (Media)

Tel: (212) 677-7632

mbeckerich@dorland.com


'/>"/>
SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference
2. SuperGen to Announce 2007 Third Quarter Financial Results October 29, 2007
3. SuperGen Reports 2007 Third Quarter Financial Results
4. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
5. SuperGen to Present at the Collins Stewart Growth Conference on July 9, 2008
6. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
7. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
8. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
9. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
10. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
11. AtriCure to Present at Roth Capital Partners 2007 New York Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... My T Chai, a South African company ... available for purchase on RevNutrition.com, a popular website specializing in sales of nutritional products. ... in ancient India and Siam. It spread across Asia and Africa quickly, and today ...
(Date:4/24/2017)... HOUSTON, TEXAS (PRWEB) , ... April 24, 2017 ... ... service (SaaS) based healthcare compliance and credentialing solutions, today announced that Kyle Allain ... Allain leads symplr’s Cactus Provider Management sales and operations, including provider, payor and ...
(Date:4/24/2017)... ... April 24, 2017 , ... In 2017, up to ... approximately 25,000 of them will be malignant.(1) As research into precision medicine continues, ... healthcare model in the diagnosis and treatment of brain tumors. Healthcare facilities that ...
(Date:4/24/2017)... , ... April 24, 2017 , ... Rod Burkett, CEO ... Housing News website. , Rod has been at the forefront of Gardant since it ... As CEO, Rod has overseen the opening of more than 40 new senior living ...
(Date:4/24/2017)... ... ... As a former supermodel known for her timeless beauty, Joan Severance knows ... is that she put all the words in her new book, "Manifest Your Mate: ... and sparkling sense of humor have inspired her to write a book on how ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... 19, 2017  SARES•REGIS Group leased the first ... at Conejo Spectrum Business Park in ... Biotherapeutics, Inc. , a biopharmaceutical company developing meaningful ... that have been underserved by scientific innovation, with ... cancer, autoimmune and infectious disease. Before ...
(Date:4/18/2017)... Research and Markets has announced the addition ... their offering. ... devices market to grow at a CAGR of 6.35% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
Breaking Medicine Technology: